Finally, IFNAR1 blockade attenuated EGF-TKI-induced Gal-9 expression and synergized with afatinib to reduce tumorigenesis in vivo [236], thus also underscoring targeting of the Gal-9-IFN axis as a promising cancer therapeutic strategy. The gene discussed is LGALS9; the disease is cancer.